Previous Close | 46.35 |
1-Year Change | 37.66% |
6-Months Change | 1.31% |
3-Months Change | 3.78% |
Moving Avg (50d) | 48.227 |
Moving Avg (200d) | 45.168 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.21B |
Beta (3-Years) | 1.59 |
Revenue Growth (ttm) | 16.3% |
Net Profit Margin (ttm) | -5.54% |
Return On Assets (ttm) | -3.22% |
EPS (ttm) | -0.22 |
PE Ratio (ttm) | -210.68 |
Dividend Yield | % |
Asset Description: | Vericel Corporation |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
45.423 | 44.032 | 43.105 | 41.715 | 39.397 | 37.08 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |